Testing blood DNA fragments to monitor cancer treatment
Part of Cancer clinical trials.
This study looks at small DNA pieces in blood to help monitor and guide cancer therapy decisions. It may help the research team understand how these blood markers relate to treatment planning for advanced cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older
- You have advanced cancer
- You can understand the study and sign the consent forms
- Your care team plans to do tumor testing called tumor-normal sequencing (often as part of the diagnostic work-up)
- The Molecular Tumor Board (MTB) should recommend a cancer therapy plan for you
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study uses advanced DNA sequencing to figure out unclear or unusual blood (hematologic) conditions when standard tests are not enough. It may help your care team reach a more accurate diagnosis by better understanding what’s driving your illness.
This study checks whether a blood test can find tumor genetic changes (called “plasma genomic profiling”) to help choose the best next treatment. It may help your care team decide therapy after your cancer progresses or seems likely to progress soon.
This trial uses special lab tests to look for tumor “molecular fingerprints” in your tumor or blood sample. The goal is to help your care team choose more personalized treatment options based on those results.
This study uses a simple blood test to look at the genetic makeup of your tumor. The results may help your doctors choose the best treatment for you. You will need to provide a tumor sample or have a biopsy.
This study uses advanced DNA testing on tumor samples to help match cancer treatments more precisely. It may help researchers learn which cancer changes are driving your tumor and how they relate to treatment choices.
This study uses gene testing on stored tumor tissue (and a blood sample) to help doctors recommend treatment options that may fit your tumor’s specific changes. It may also help avoid certain medicines and share your de-identified data with other researchers.
Hear when a new Next-Generation-Sequencing trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.